RevisiónSarcoma de Kaposi y angiosarcoma cutáneo: directrices para el diagnóstico y tratamientoKaposi Sarcoma and Cutaneous Angiosarcoma: Guidelines for Diagnosis and Treatment
Graphical abstract
Section snippets
Sarcoma de Kaposi
El sarcoma de Kaposi (SK) es un tumor angioproliferativo asociado a la infección por virus herpes humano tipo 8 (VHH-8)1, 2. Se describen 4 variantes (tabla 1):
Sarcoma de Kaposi clásico. Es un tumor infrecuente que afecta a hombres1, 3 del área mediterránea o centroeuropea, con una incidencia entre 0,18-13,2 casos/1064, siendo más frecuente en hombres con edema crónico de piernas, diabetes mellitus y usuarios de corticoides. Se presenta como placas o nódulos eritematovioláceos, únicos o
Angiosarcoma cutáneo
Los angiosarcomas representan entre el 1 y el 2%25, 26 de todos los sarcomas, pero al menos la mitad de ellos son cutáneos. De los sarcomas cutáneos, el angiosarcoma es el cuarto en frecuencia, por detrás del sarcoma de Kaposi, el dermatofibrosarcoma y el leiomiosarcoma. El angiosarcoma cutáneo es una de las neoplasias cutáneas de peor pronóstico, con supervivencia a los 5 años de entre el 10% en las series más antiguas27 y el 30 y el 50% en las más modernas25, 28, 29. Existen 3 grandes
Conflicto de intereses
Los autores declaran no tener ningún conflicto de intereses.
Bibliografía (62)
- et al.
Classic Kaposi sarcoma in the United States over the last two decades: A clinicopathologic and molecular study of 438 non-HIV-related Kaposi sarcoma patients with comparison to HIV-related Kaposi sarcoma
Mod Pathol.
(2008) - et al.
Treatments for classic Kaposi sarcoma: A systematic review of the literature
J Am Acad Dermatol.
(2013) - et al.
Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: A multicenter study
J Invest Dermatol.
(2008) - et al.
Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection
J Am Acad Dermatol.
(1993) - et al.
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: A retrospective study of 161 cases
Ann Oncol
(2007) - et al.
Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007
Ann Diagn Pathol.
(2011) - et al.
Cutaneous angiosarcoma: A case series with prognostic correlation
J Am Acad Dermatol.
(2004) - et al.
Cutaneous vascular proliferations. Part III. Malignant neoplasms, other cutaneous neoplasms with significant vascular component, and disorders erroneously considered as vascular neoplasms
J Am Acad Dermatol
(1998) - et al.
Vascular tumors of the skin: A selective review
Semin Diagn Pathol
(2004) - et al.
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema
Am J Pathol
(2010)
Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: Clinicopathological, immunohistochemical and molecular analysis of 66 cases
Mod Pathol.
MYC amplification and overexpression in primary cutaneous angiosarcoma: A fluorescence in-situ hybridization and immunohistochemical study
Mod Pathol.
MYC immunohistochemistry in angiosarcoma and atypical vascular lesions: Practical considerations based on a single institutional experience
Pathology.
Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas
Mod Pathol.
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium
Am J Pathol
Cutaneous angiosarcoma of head and neck: A new predictive score for locoregional metastasis
Transl Oncol.
Prognostic features in angiosarcoma of the head and neck: A retrospective monocenter study
J Craniomaxillofac Surg.
Surgical management of radiation-associated cutaneous breast angiosarcoma
J Plast Reconstr Aesthet Surg.
Durable response of angiosarcoma of the face and scalp to docetaxel
Clin Oncol (R Coll Radiol).
Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: A bench to bedside study
EBioMedicine.
Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study
Int J Cancer.
Tailoring treatment for classical Kaposi's sarcoma: Comprehensive clinical guidelines
Int J Oncol.
Kaposi's sarcoma in Italy before and after the AIDS epidemic
Br J Cancer.
Kaposi's Sarcoma after kidney transplantation: A 21-years experience
Int J Hematol Oncol Stem Cell Res.
Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement
J Clin Oncol
Kaposi's sarcoma in HIV-negative men having sex with men
AIDS
AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification AIDS Clinical Trials Group Oncology Committee
J Clin Oncol.
Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: A retrospective study
Cancer.
Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine
Cancer.
Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma
J Clin Oncol.
Cited by (29)
Skin lesions in a patient recently diagnosed with HIV
2023, FMC Formacion Medica Continuada en Atencion PrimariaEmerging therapies for rare cutaneous cancers: A systematic review
2021, Cancer Treatment ReviewsCitation Excerpt :Of note, however, response rate to treatment were below 60% in clinical trials and neutropenia was a concern for all studies [7]. Pegylated liposomal doxorubicin (PLD) is commonly used for disseminated disease in patients with or without HIV, while pomalidomide is preferred for refractory therapy [46]. Anti-proliferative agents, including pomalidomide and lenalidomide, have clinical trials with the most active recruitment, aligning with NCCN guidelines for systemic therapy and clinical trial enrollment.
Kaposi's sarcoma: a single-center experience on 38 patients
2021, Anais Brasileiros de Dermatologia